• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640408)   Today's Articles (187)   Subscriber (50346)
For: Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32. [PMID: 21343556 DOI: 10.1200/jco.2010.31.3304] [Citation(s) in RCA: 822] [Impact Index Per Article: 63.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]  Open
Number Cited by Other Article(s)
751
Rachner TD, Hadji P, Hofbauer LC. Novel therapies in benign and malignant bone diseases. Pharmacol Ther 2012;134:338-44. [PMID: 22401778 DOI: 10.1016/j.pharmthera.2012.02.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Accepted: 02/15/2012] [Indexed: 01/31/2023]
752
New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol 2012;29:S1-8. [PMID: 22074657 DOI: 10.1016/j.urolonc.2011.08.013] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2011] [Revised: 08/24/2011] [Accepted: 08/24/2011] [Indexed: 11/20/2022]
753
Role of denosumab in prostate cancer. Prostate Cancer Prostatic Dis 2012;15:231-6. [PMID: 22370723 DOI: 10.1038/pcan.2012.2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
754
Bundred N. Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 2012;38:776-86. [PMID: 22370427 DOI: 10.1016/j.ctrv.2012.02.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Revised: 01/13/2012] [Accepted: 02/02/2012] [Indexed: 11/16/2022]
755
Talreja DB. Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assess 2012;1:30-3. [PMID: 27536425 PMCID: PMC4980727 DOI: 10.3109/21556660.2012.668504] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/16/2012] [Indexed: 01/14/2023]  Open
756
Metcalf S, Pandha HS, Morgan R. Antiangiogenic effects of zoledronate on cancer neovasculature. Future Oncol 2012;7:1325-33. [PMID: 22044205 DOI: 10.2217/fon.11.113] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]  Open
757
Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor. Pharmacotherapy 2012;32:274-84. [PMID: 22392458 DOI: 10.1002/j.1875-9114.2011.01092.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
758
Beach DF, Somer RA, Hoffman-Censits J, Lin J, Wong YN, Plimack E, Plimeck E, Hudes G, Vaughn D, Bernstein GT, Morris GJ. A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer. Semin Oncol 2012;39:1-8. [PMID: 22289486 DOI: 10.1053/j.seminoncol.2011.11.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
759
Lee BL, Higgins MJ, Goss PE. Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol 2012;51:157-67. [PMID: 22150116 DOI: 10.3109/0284186x.2011.633555] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
760
Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A. New understanding and treatments for osteoporosis. Endocrine 2012;41:58-69. [PMID: 22180055 DOI: 10.1007/s12020-011-9570-2] [Citation(s) in RCA: 114] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
761
The Medical Research Council Myeloma IX Trial: New Clinical Insights on the Anticancer Effects of Zoledronic Acid in Patients With Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2012;12:2-4. [DOI: 10.1016/j.clml.2011.03.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Revised: 03/08/2011] [Accepted: 03/11/2011] [Indexed: 11/19/2022]
762
Saylor PJ, Michaelson MD. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer? Oncologist 2012;17:288-90. [PMID: 22267850 DOI: 10.1634/theoncologist.2011-0433] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
763
Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 2012;9:110-8. [PMID: 22231759 DOI: 10.1038/nrclinonc.2011.197] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
764
Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15:712-23. [PMID: 22409231 DOI: 10.3111/13696998.2012.675380] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
765
Morgan GJ, Wu P. Targeting bone in myeloma. Recent Results Cancer Res 2012;192:127-143. [PMID: 22307373 DOI: 10.1007/978-3-642-21892-7_6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
766
Watts NB, Roux C, Modlin JF, Brown JP, Daniels A, Jackson S, Smith S, Zack DJ, Zhou L, Grauer A, Ferrari S. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2012;23:327-37. [PMID: 21892677 PMCID: PMC3249159 DOI: 10.1007/s00198-011-1755-2] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Accepted: 06/23/2011] [Indexed: 01/29/2023]
767
Ortiz A, Lin SH. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum? Recent Results Cancer Res 2012;192:225-33. [PMID: 22307378 DOI: 10.1007/978-3-642-21892-7_11] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
768
Morikawa K, Mineshita M, Nishine H, Furuya N, Obayashi J, Miyazawa T. A Case of Squamous Cell Lung Carcinoma with Bone Metastasis Responding to Denosumab After Zoledronic Acid Hydrate. ACTA ACUST UNITED AC 2012. [DOI: 10.2482/haigan.52.1035] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
769
Body JJ. Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther 2011;12:307-22. [PMID: 22192269 DOI: 10.1586/era.11.204] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
770
Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol 2011;9:76-8. [PMID: 22182971 DOI: 10.1038/nrclinonc.2011.198] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
771
OPG/RANKL/RANK pathway as a therapeutic target in cancer. J Thorac Oncol 2011;6:1468-73. [PMID: 21849854 DOI: 10.1097/jto.0b013e318229421f] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
772
Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin Pharmacol Ther 2011;91:123-33. [PMID: 22158568 DOI: 10.1038/clpt.2011.268] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
773
Scott LJ, Muir VJ. Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumors: profile report. BioDrugs 2011;25:397-400. [PMID: 22050342 DOI: 10.2165/11207650-000000000-00000] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
774
Kennedy K, Patel H. Update on the pharmacological prevention of skeletal-related events in cancer patients. Orthopedics 2011;34:982-5. [PMID: 22147215 DOI: 10.3928/01477447-20111021-21] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
775
Lewiecki EM. Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. DRUG HEALTHCARE AND PATIENT SAFETY 2011;3:79-91. [PMID: 22279412 PMCID: PMC3264422 DOI: 10.2147/dhps.s7727] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
776
Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011;22:2951-61. [PMID: 21997225 DOI: 10.1007/s00198-011-1804-x] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2011] [Accepted: 09/23/2011] [Indexed: 01/08/2023]
777
Tsourdi E, Rachner TD, Rauner M, Hamann C, Hofbauer LC. Denosumab for bone diseases: translating bone biology into targeted therapy. Eur J Endocrinol 2011;165:833-40. [PMID: 21852390 DOI: 10.1530/eje-11-0454] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
778
Reuben JS. Bisphosphonates that lack a nitrogen-containing side chain do not cause osteonecrosis of the jaws, regardless of their effect on STAT3 phosphorylation and SOCS3 expression. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.tripleo.2011.04.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
779
Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 2011;8:90-6. [DOI: 10.1038/nrrheum.2011.181] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
780
Arslan C, Altundag K, Dizdar O. Emerging drugs in metastatic breast cancer: an update. Expert Opin Emerg Drugs 2011;16:647-67. [PMID: 22122529 DOI: 10.1517/14728214.2011.640672] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
781
Steger GG, Bartsch R. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 2011;3:233-43. [PMID: 21957430 DOI: 10.1177/1758834011412656] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
782
Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Crit Rev Oncol Hematol 2011;80:301-13. [DOI: 10.1016/j.critrevonc.2011.03.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2010] [Revised: 03/10/2011] [Accepted: 03/24/2011] [Indexed: 01/30/2023]  Open
783
Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CHM, Kane CJ, Jamieson CAM. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med 2011;9:185. [PMID: 22035283 PMCID: PMC3269442 DOI: 10.1186/1479-5876-9-185] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2011] [Accepted: 10/28/2011] [Indexed: 02/07/2023]  Open
784
Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 2011;18:326-35. [PMID: 22031096 DOI: 10.1158/1078-0432.ccr-10-2507] [Citation(s) in RCA: 159] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
785
Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone 2011;49:710-6. [PMID: 21807133 DOI: 10.1016/j.bone.2011.07.020] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Revised: 07/11/2011] [Accepted: 07/13/2011] [Indexed: 01/13/2023]
786
&NA;. Denosumab: a guide to its use in treating or preventing bone disease in various patient populations. DRUGS & THERAPY PERSPECTIVES 2011. [DOI: 10.2165/11601580-000000000-00000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
787
New developments for treatment and prevention of bone metastases. Curr Opin Oncol 2011;23:338-42. [PMID: 21519257 DOI: 10.1097/cco.0b013e328347918b] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
788
Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011;29:3705-14. [PMID: 21860001 PMCID: PMC3675709 DOI: 10.1200/jco.2010.34.4994] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Accepted: 06/23/2011] [Indexed: 11/20/2022]  Open
789
Antitumor effects of bisphosphonates. Curr Opin Support Palliat Care 2011;5:233-40. [DOI: 10.1097/spc.0b013e328349dc17] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
790
Denosumab. Curr Opin Support Palliat Care 2011;5:258-64. [DOI: 10.1097/spc.0b013e328349731c] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
791
[The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]. Bull Cancer 2011;98:837-46. [PMID: 21700551 DOI: 10.1684/bdc.2011.1398] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
792
Noonan K, Borrello I. The immune microenvironment of myeloma. CANCER MICROENVIRONMENT 2011;4:313-23. [PMID: 21866321 DOI: 10.1007/s12307-011-0086-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2011] [Accepted: 08/11/2011] [Indexed: 12/16/2022]
793
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2011;26:199-213. [PMID: 21852787 DOI: 10.1038/leu.2011.214] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
794
Wu P, Morgan GJ. Targeting bone as a therapy for myeloma. CANCER MICROENVIRONMENT 2011;4:299-311. [PMID: 21833747 DOI: 10.1007/s12307-011-0079-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2011] [Accepted: 07/18/2011] [Indexed: 01/10/2023]
795
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer 2011;19:1687-96. [PMID: 21785900 DOI: 10.1007/s00520-011-1230-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Accepted: 07/04/2011] [Indexed: 01/25/2023]
796
Sorscher SM, Lockhart AC. Ras Inhibition and the Survival Benefit Favoring Zoledronic Acid Compared With Denosumab in Patients With Multiple Myeloma. J Clin Oncol 2011;29:2735-6; author reply 2736-8. [DOI: 10.1200/jco.2011.35.8333] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
797
Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O. Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn 2011;11:593-603. [PMID: 21745013 PMCID: PMC3199399 DOI: 10.1586/erm.11.44] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
798
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Reply to S.M. Sorscher et al. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.35.9182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
799
Aft R, Perez JR, Raje N, Hirsh V, Saad F. Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. Crit Rev Oncol Hematol 2011;82:233-48. [PMID: 21683613 DOI: 10.1016/j.critrevonc.2011.05.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Revised: 05/18/2011] [Accepted: 05/25/2011] [Indexed: 12/12/2022]  Open
800
Calderone R, Nimako K, Leary A, Popat S, O'Brien MER. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication. Eur J Cancer 2011;47:1603-5. [PMID: 21684152 DOI: 10.1016/j.ejca.2011.05.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2011] [Accepted: 05/06/2011] [Indexed: 11/25/2022]
PrevPage 16 of 17 121314151617Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA